The DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.
Immunological Approaches Towards Cancer and Inflammation: A Cross Talk
Open accessAbstract
The inflammation is the protective response of the body against various harmful stimuli, however, the aberrant and inappropriate activation tends to become harmful. The acute inflammatory response tends to resolved once the offending agent is subside but this acute response becomes chronic in nature when the body is unable to successfully neutralized the noxious stimuli. This chronic inflammatory microenvironment is associated with the release of various pro-inflammatory and oncogenic mediators such as nitric oxide (NO), cytokines (IL-1β, IL-2, IL-6 and TNF-α), growth factor and chemokines. These mediators make the inflammatory microenvironment more vulnerable towards tumorigenesis. The pro-inflammatory mediators released during the chronic inflammation tends to induce several molecular signaling cascades such as NF-κB, MAPKinase, Nrf2, Pi3K, JAK/STAT, Wnt/B-catenin, and CREB. The immune system and its components have a pleiotropic effect on inflammation and cancer progression. Immune components such as T cells, NK cells, macrophages, and neutrophils either inhibit or enhance tumor initiation depending upon the type of tumor and immune cells involved. Tumor-associated macrophages (TAMs) and tumor-associated neutrophils (TANs) are pro-tumorigenic cells highly prevalent in inflammation-mediated tumors. Similarly, presence of T regulatory (Treg) cells in an inflammatory and tumor setting suppresses the immune system, thus paving the way for oncogenesis. However, Treg cells also inhibit autoimmune inflammation. In contrast, cytotoxic T cells and T helper cells confer anti-tumor immunity and are associated with better prognosis in patients with cancer. Cytotoxic T cells inflict a direct cytotoxic effect on cells expressing oncogenic markers. Currently, several anti-inflammatory and anti-tumor therapies are under trials in which these immune cells are exploited. Adoptive cell transfer (ACT) comprised of tumor infiltrating lymphocytes (TILs) has been tried for the treatment of tumors after their ex vivo expansion. Mediators released by cells in a tumorigenic and inflammatory microenvironment cross talk with nearby cells, either promoting or inhibiting inflammation and cancer. Recently, several cytokine-based therapies are either being developed or are under trial to treat such types of manifestations. Monoclonal antibodies directed against TNF-α, VEGF, and IL-6 has shown promising results to ameliorate inflammation and cancer, while direct administration of IL-2 has been shown to cause tumor regression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Pathogen Recognition and Innate Immunity
Akira, S., Uematsu, S., & Takeuchi, O. (2006) · Cell · doi:10.1016/j.cell.2006.02.015 · Cited by 11,952
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Macrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668
Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN
Fridlender, Z. G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., Worthen, G. S., & Albelda, S. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.017 · Cited by 3,371
The risk of colorectal cancer in ulcerative colitis: a meta-analysis
Eaden, J. A., Abrams, K. R., & Mayberry, J. F. (2001) · Gut · doi:10.1136/gut.48.4.526 · Cited by 2,959
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability
Colotta, F., Allavena, P., Sica, A., Garlanda, C., & Mantovani, A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp127 · Cited by 2,890
HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS
Beasley, R. P., Lin, C.-C., Hwang, L.-Y., & Chien, C.-S. (1981) · The Lancet · doi:10.1016/s0140-6736(81)90585-7 · Cited by 2,865
Innate or adaptive immunity? The example of natural killer cells
Vivier, E., Raulet, D. H., Moretta, A., Caligiuri, M. A., Zitvogel, L., Lanier, L. L., Yokoyama, W. M., & Ugolini, S. (2011) · Science · doi:10.1126/science.1198687 · Cited by 2,824
Points of control in inflammation
Nathan, C. (2002) · Nature · doi:10.1038/nature01320 · Cited by 2,738
Innate Immune Activation Through Nalp3 Inflammasome Sensing of Asbestos and Silica
Dostert, C., Pétrilli, V., Van Bruggen, R., Steele, C., Mossman, B. T., & Tschopp, J. (2008) · Science · doi:10.1126/science.1156995 · Cited by 2,658
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
Paradoxical roles of the immune system during cancer development
de Visser, K. E., Eichten, A., & Coussens, L. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1782 · Cited by 2,256
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164
Control of adaptive immunity by the innate immune system
Iwasaki, A., & Medzhitov, R. (2015) · Nature Immunology · doi:10.1038/ni.3123 · Cited by 2,160 · cited 3×
“The innate immune system confronts pathogens via a large number of diverse pathogen-recognition receptors (PRRs) and by the generation of nonselective and random antigen-specific receptors molecules (81).”
BackgroundInfluentialTumour necrosis factor and cancer
Balkwill, F. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2628 · Cited by 1,915
Neutrophil Function: From Mechanisms to Disease
Amulic, B., Cazalet, C., Hayes, G. L., Metzler, K. D., & Zychlinsky, A. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-074942 · Cited by 1,708
Interferons, immunity and cancer immunoediting
Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1961 · Cited by 1,617
Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer
Yamamoto, Y., & Gaynor, R. B. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11914 · Cited by 1,585
Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution
Taguchi, K., Motohashi, H., & Yamamoto, M. (2011) · Genes to Cells · doi:10.1111/j.1365-2443.2010.01473.x · Cited by 1,478
NF-κB Controls Cell Growth and Differentiation through Transcriptional Regulation of Cyclin D1
Guttridge, D. C., Albanese, C., Reuther, J. Y., Pestell, R. G., & Baldwin, A. S. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.8.5785 · Cited by 1,312
IL-2: The First Effective Immunotherapy for Human Cancer
Rosenberg, S. A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1490019 · Cited by 1,289
Intracellular pattern recognition receptors in the host response
Meylan, E., Tschopp, J., & Karin, M. (2006) · Nature · doi:10.1038/nature04946 · Cited by 1,206
Non-canonical NF-κB signaling pathway
Sun, S.-C. (2011) · Cell Research · doi:10.1038/cr.2010.177 · Cited by 1,197
Pasparakis, M., Alexopoulou, L., Episkopou, V, & Kollias, G. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.4.1397 · Cited by 1,160
Berg, D. J., Davidson, N., Kühn, R., Müller, W., Menon, S., Holland, G., Thompson-Snipes, L., Leach, M. W., & Rennick, D. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118861 · Cited by 1,136
Inflammation and cancer: An ancient link with novel potentials
Perwez Hussain, S., & Harris, C. C. (2007) · International Journal of Cancer · doi:10.1002/ijc.23173 · Cited by 1,097
Mechanistic Studies of the Nrf2-Keap1 Signaling Pathway
Zhang, D. D. (2006) · Drug Metabolism Reviews · doi:10.1080/03602530600971974 · Cited by 1,086
Martin, M., Rehani, K., Jope, R. S., & Michalek, S. M. (2005) · Nature Immunology · doi:10.1038/ni1221 · Cited by 1,080
Inflammation, a Key Event in Cancer Development
Lu, H., Ouyang, W., & Huang, C. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0261 · Cited by 1,028
Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke–induced emphysema in mice
Rangasamy, T., Cho, C. Y., Thimmulappa, R. K., Zhen, L., Srisuma, S. S., Kensler, T. W., Yamamoto, M., Petrache, I., Tuder, R. M., & Biswal, S. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421146 · Cited by 991
TGF-β Activation and Function in Immunity
Travis, M. A., & Sheppard, D. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120257 · Cited by 856
IL-6: From its discovery to clinical applications
Kishimoto, T. (2010) · International Immunology · doi:10.1093/intimm/dxq030 · Cited by 846
Steele, C. W., Karim, S. A., Leach, J. D. G., Bailey, P., Upstill-Goddard, R., Rishi, L., Foth, M., Bryson, S., McDaid, K., Wilson, Z., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.014 · Cited by 845
Inflammation: Gearing the journey to cancer
KUNDU, J., & SURH, Y. (2008) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2008.03.002 · Cited by 803
Dual Roles of Immune Cells and Their Factors in Cancer Development and Progression
Zamarron, B. F., & Chen, W. (2011) · International Journal of Biological Sciences · doi:10.7150/ijbs.7.651 · Cited by 681
DeNardo, D. G., & Coussens, L. M. (2007) · Breast Cancer Research · doi:10.1186/bcr1746 · Cited by 677
TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway
Viel, S., Marçais, A., Guimaraes, F. S.-F., Loftus, R., Rabilloud, J., Grau, M., Degouve, S., Djebali, S., Sanlaville, A., Charrier, E., et al. (2016) · Science Signaling · doi:10.1126/scisignal.aad1884 · Cited by 672
Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways
Schetter, A. J., Heegaard, N. H. H., & Harris, C. C. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp272 · Cited by 657
Candido, J., & Hagemann, T. (2013) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9847-0 · Cited by 653
Mechanism of TGF-β signaling to growth arrest, apoptosis, and epithelial–mesenchymal transition
Heldin, C.-H., Landström, M., & Moustakas, A. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.01.021 · Cited by 634
Neutrophils in the tumor microenvironment
Powell, D. R., & Huttenlocher, A. (2016) · Trends in Immunology · doi:10.1016/j.it.2015.11.008 · Cited by 578
Autophagy, Inflammation, and Immunity: A Troika Governing Cancer and Its Treatment
Zhong, Z., Sanchez-Lopez, E., & Karin, M. (2016) · Cell · doi:10.1016/j.cell.2016.05.051 · Cited by 576
Johnson, D. B., Estrada, M. V., Salgado, R., Sanchez, V., Doxie, D. B., Opalenik, S. R., Vilgelm, A. E., Feld, E., Johnson, A. S., Greenplate, A. R., et al. (2016) · Nature Communications · doi:10.1038/ncomms10582 · Cited by 566
Triantafillidis, J. K., Nasioulas, G., & Kosmidis, P. (2009) · PubMed · Cited by 559
NIOI, P., McMAHON, M., ITOH, K., YAMAMOTO, M., & HAYES, J. D. (2003) · Biochemical Journal · doi:10.1042/bj20030754 · Cited by 507
Inflammation and oncogenesis: a vicious connection
Grivennikov, S. I., & Karin, M. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.11.004 · Cited by 456
Takano, S., Yokosuka, O., Imazeki, F., Tagawa, M., & Omata, M. (1995) · Hepatology · doi:10.1002/hep.1840210308 · Cited by 432
Mellor, J. D., Brown, M. P., Irving, H. R., Zalcberg, J. R., & Dobrovic, A. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-1 · Cited by 415
Inflammation and Lung Cancer: Roles of Reactive Oxygen/Nitrogen Species
Azad, N., Rojanasakul, Y., & Vallyathan, V. (2008) · Journal of Toxicology and Environmental Health, Part B · doi:10.1080/10937400701436460 · Cited by 409
CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells
Liu, X., Zhang, Y., Cheng, C., Cheng, A. W., Zhang, X., Li, N., Xia, C., Wei, X., Liu, X., & Wang, H. (2017) · Cell Research · doi:10.1038/cr.2016.142 · Cited by 396
A systematic review of geographical variation in access to chemotherapy
Chamberlain, C., Owen-Smith, A., Donovan, J., & Hollingworth, W. (2016) · BMC Cancer · doi:10.1186/s12885-015-2026-y · Cited by 390
Navegantes, K. C., de Souza Gomes, R., Pereira, P. A. T., Czaikoski, P. G., Azevedo, C. H. M., & Monteiro, M. C. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1141-8 · Cited by 358
Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophillic phase II inducers
Satoh, T., Okamoto, S.-I., Cui, J., Watanabe, Y., Furuta, K., Suzuki, M., Tohyama, K., & Lipton, S. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505723102 · Cited by 341
Self-medication among medical and pharmacy students in Bangladesh
Alam, N., Saffoon, N., & Uddin, R. (2015) · BMC Research Notes · doi:10.1186/s13104-015-1737-0 · Cited by 334
Rapid recruitment of inflammatory monocytes is independent of neutrophil migration
Henderson, R. B., Hobbs, J. A. R., Mathies, M., & Hogg, N. (2003) · Blood · doi:10.1182/blood-2002-10-3228 · Cited by 309
Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?
Bui, J. D., & Schreiber, R. D. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.02.001 · Cited by 303
Ben-Baruch, A. (2002) · Breast Cancer Research · doi:10.1186/bcr554 · Cited by 300
Bekes, E. M., Schweighofer, B., Kupriyanova, T. A., Zajac, E., Ardi, V. C., Quigley, J. P., & Deryugina, E. I. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.05.031 · Cited by 298
Trellakis, S., Bruderek, K., Dumitru, C. A., Gholaman, H., Gu, X., Bankfalvi, A., Scherag, A., Hütte, J., Dominas, N., Lehnerdt, G. F., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.25892 · Cited by 281
Eaton, K. A., Mefford, M., & Thevenot, T. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.12.7456 · Cited by 280
Ortega-Martínez, S. (2015) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2015.00046 · Cited by 278
Wang, M., Tan, Z., Zhang, R., Kotenko, S. V., & Liang, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106043200 · Cited by 269
Oxidative stress inactivates the human DNA mismatch repair system
Chang, C. L., Marra, G., Chauhan, D. P., Ha, H. T., Chang, D. K., Ricciardiello, L., Randolph, A., Carethers, J. M., & Boland, C. R. (2002) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00422.2001 · Cited by 262
Mohammed, M. K., Shao, C., Wang, J., Wei, Q., Wang, X., Collier, Z., Tang, S., Liu, H., Zhang, F., Huang, J., et al. (2016) · Genes & Diseases · doi:10.1016/j.gendis.2015.12.004 · Cited by 259
Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
Akinleye, A., Avvaru, P., Furqan, M., Song, Y., & Liu, D. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-88 · Cited by 254
Wnt and the Wnt signaling pathway in bone development and disease
Wang, Y. (2014) · Frontiers in Bioscience · doi:10.2741/4214 · Cited by 248
Yang, K., Wang, X., Zhang, H., Wang, Z., Nan, G., Li, Y., Zhang, F., Mohammed, M. K., Haydon, R. C., Luu, H. H., et al. (2016) · Laboratory Investigation · doi:10.1038/labinvest.2015.144 · Cited by 241
The Mitogen-Activated Protein Kinase (MAPK) Pathway: Role in Immune Evasion by Trypanosomatids
Soares-Silva, M., Diniz, F. F., Gomes, G. N., & Bahia, D. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00183 · Cited by 232
Inflammation and cancer: Role of nuclear factor‐kappaB activation
Maeda, S., & Omata, M. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00763.x · Cited by 231
The way Wnt works: Components and mechanism
Saito-Diaz, K., Chen, T. W., Wang, X., Thorne, C. A., Wallace, H. A., Page-McCaw, A., & Lee, E. (2013) · Growth Factors · doi:10.3109/08977194.2012.752737 · Cited by 215
JAK-STAT signaling in cancer: From cytokines to non-coding genome
Pencik, J., Pham, H. T. T., Schmoellerl, J., Javaheri, T., Schlederer, M., Culig, Z., Merkel, O., Moriggl, R., Grebien, F., & Kenner, L. (2016) · Cytokine · doi:10.1016/j.cyto.2016.06.017 · Cited by 215
Mukherjee, P., Bhattacharya, R., Bone, N., Lee, Y. K., Patra, C., Wang, S., Lu, L., Secreto, C., Banerjee, P. C., Yaszemski, M. J., et al. (2007) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-5-4 · Cited by 208
Punturieri, A., Szabo, E., Croxton, T. L., Shapiro, S. D., & Dubinett, S. M. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp023 · Cited by 197
Pahler, J. C., Tazzyman, S., Erez, N., Chen, Y.-Y., Murdoch, C., Nozawa, H., Lewis, C. E., & Hanahan, D. (2008) · Neoplasia · doi:10.1593/neo.07871 · Cited by 184
Inhibition of IL-1, IL-6, and TNF-α in immune-mediated inflammatory diseases
Möller, B., & Villiger, P. M. (2006) · Springer Seminars in Immunopathology · doi:10.1007/s00281-006-0012-9 · Cited by 183
Somasundaram, R., Jacob, L., Swoboda, R., Caputo, L., Song, H., Basak, S. K., Monos, D. S., Peritt, D., Marincola, F. M., Cai, D., et al. (2002) · PubMed · Cited by 181
Ramesh, R., Mhashilkar, A. M., Tanaka, F., Saito, Y., Branch, C. D., Sieger, K., Mumm, J. B., Stewart, A., Boquoi, A., Dumoutier, L., et al. (2003) · PubMed · Cited by 178
The Keap1–Nrf2 Cell Defense Pathway – A Promising Therapeutic Target?
Copple, I. M. (2012) · Advances in Pharmacology · doi:10.1016/b978-0-12-398339-8.00002-1 · Cited by 171
Cells of the innate and adaptive immunity and their interactions in inflammatory bowel disease
Kmieć, Z., Cyman, M., & Ślebioda, T. J. (2017) · Advances in Medical Sciences · doi:10.1016/j.advms.2016.09.001 · Cited by 168
Caught in the cross fire: p53 in inflammation
Cooks, T., Harris, C. C., & Oren, M. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu134 · Cited by 162
Gotthardt, D., Putz, E. M., Grundschober, E., Prchal‐Murphy, M., Straka, E., Kudweis, P., Heller, G., Bagó-Horváth, Z., Witalisz‐Siepracka, A., Cumaraswamy, A. A., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0732 · Cited by 158
Role of Mononuclear Cells and Inflammatory Cytokines in Pancreatic Cancer-Related Cachexia
Martignoni, M. E., Kunze, P., Hildebrandt, W., Künzli, B. M., Berberat, P. O., Giese, T., Klöters, O., Hammer, J., Büchler, M. W., Giese, N. A., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0185 · Cited by 157
Kim, S. S., Harford, J. B., Pirollo, K. F., & Chang, E. H. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.06.137 · Cited by 155
Interleukins 1 and 6 as main mediators of inflammation and cancer
Dmitrieva, O., Shilovskiy, I. P., Khaitov, M. R., & Grivennikov, S. I. (2016) · Biochemistry (Moscow) · doi:10.1134/s0006297916020024 · Cited by 155
Hatfield, S. M., & Sitkovsky, M. V. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.06.009 · Cited by 155
Chen, D., Si, W., Shen, J., Du, C., Lou, W., Bao, C., Zheng, H., Pan, J., Zhong, G., Xu, L., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0211-4 · Cited by 153
Steven, A., & Seliger, B. (2016) · Oncotarget · doi:10.18632/oncotarget.7721 · Cited by 150
Polymeric nanomedicines for image-guided drug delivery and tumor-targeted combination therapy
Lammers, T., Šubr, V., Ulbrich, K., Hennink, W. E., Storm, G., & Kiessling, F. M. (2010) · Nano Today · doi:10.1016/j.nantod.2010.05.001 · Cited by 145
Dismicrobism in inflammatory bowel disease and colorectal cancer: Changes in response of colocytes
Tomasello, G., Tralongo, P., Damiani, P., Sinagra, E., Trapani, B. D., Zeenny, M. N., Hussein, I. H., Jurjus, A., & Leone, A. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i48.18121 · Cited by 138
Immunotherapy for the Treatment of Urothelial Carcinoma
Donin, N. M., Lenis, A. T., Holden, S., Drakaki, A., Pantuck, A. J., Belldegrun, A. S., & Chamie, K. (2016) · The Journal of Urology · doi:10.1016/j.juro.2016.02.3005 · Cited by 137
Tumor-associated macrophages and anti-tumor therapies: complex links
Belgiovine, C., D’Incalci, M., Allavena, P., & Frapolli, R. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2166-5 · Cited by 135
Das, L., & Vinayak, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124000 · Cited by 131
Inflammatory bowel disease related innate immunity and adaptive immunity.
Huang, Y., & Chen, Z. (2016) · Europe PMC (PubMed Central) · Cited by 131
Carus, A., Ladekarl, M. B., Hager, H., Pilegaard, H. K., Nielsen, P. S., & Donskov, F. N. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.03.003 · Cited by 128
Elman, J. S., Li, M., Wang, F., Gimble, J. M., & Parekkadan, B. (2014) · Journal of Inflammation · doi:10.1186/1476-9255-11-1 · Cited by 126
Pal, S., Bhattacharjee, A., Ali, A., Mandal, N. C., Mandal, S. C., & Pal, M. (2014) · Journal of Inflammation · doi:10.1186/1476-9255-11-23 · Cited by 124
IL6 Trans-signaling Promotes KRAS-Driven Lung Carcinogenesis
Brooks, G. D., McLeod, L., Alhayyani, S., Miller, A., Russell, P. A., Ferlin, W. G., Rose‐John, S., Ruwanpura, S. M., & Jenkins, B. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2388 · Cited by 122
The phosphoinositide 3-kinase pathway and therapy resistance in cancer
Brown, K., & Toker, A. (2015) · F1000Prime Reports · doi:10.12703/p7-13 · Cited by 121
Nieborowska-Skorska, M., Słupianek, A., Xue, L., Zhang, Q., Raghunath, P. N., Hoser, G., Wasik, M. A., Morris, S. W., & Skórski, T. (2001) · PubMed · Cited by 116
Inflammation and Cancer: Is the Link as Simple as We Think?
Nickoloff, B. J., Ben-Neriah, Y., & Pikarsky, E. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23724.x · Cited by 110
Non-apoptotic cell death in malignant tumor cells and natural compounds
Ye, J., Zhang, R., Wu, F., Zhai, L., Wang, K., Xiao, M., Xie, T., & Sui, X. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.061 · Cited by 108
Key Role of Phosphoinositide 3-Kinase Class IB in Pancreatic Cancer
Edling, C. E., Selvaggi, F., Buus, R., Maffucci, T., Sebastiano, P. D., Friess, H., Innocenti, P., Kocher, H. M., & Falasca, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1210 · Cited by 107
Oxidative stress increases frameshift mutations in human colorectal cancer cells.
Gasché, C., Chang, C. L., Rhees, J., Goel, A., & Boland, C. R. (2001) · PubMed · Cited by 106
Aberrant regulation of Wnt signaling in hepatocellular carcinoma
Liu, L., Xie, S., Chen, Y.-T., Xue, J.-L., Zhang, C., & Zhu, F. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i33.7486 · Cited by 102
Yu, Q., Zeng, K., Ma, X., Song, F., Jiang, Y., Tu, P., & Wang, X. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.05.010 · Cited by 100
Petrofsky, M., & Bermudez, L. E. (1999) · Clinical Immunology · doi:10.1006/clim.1999.4709 · Cited by 99
The effector T helper cell triade.
Fietta, P., & Delsante, G. (2009) · PubMed · Cited by 96
Apoptosis‐inducing effect of garcinol is mediated by NF‐κB signaling in breast cancer cells
Ahmad, A., Wang, Z. P., Raza, A., Maitah, M. Y., Kong, D., Banerjee, S., Padhyé, S., & Sarkar, F. H. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22492 · Cited by 96
Oncogenic role of leptin and Notch interleukin-1 leptin crosstalk outcome in cancer
Lipsey, C. C., Harbuzariu, A., Daley-Brown, D. S., & Gonzalez-Perez, R. R. (2016) · World Journal of Methodology · doi:10.5662/wjm.v6.i1.43 · Cited by 96
Bladder Cancer and Genetic Mutations
Zhang, X., & Zhang, Y. (2015) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-015-0574-z · Cited by 95
Griffiths, E. A., Srivastava, P., Matsuzaki, J., Brumberger, Z. L., Wang, E. S., Kocent, J., Miller, A., Roloff, G. W., Wong, H. Y., Paluch, B. E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1792 · Cited by 94
TC-PTP and PTP1B: Regulating JAK–STAT signaling, controlling lymphoid malignancies
Pike, K. A., & Tremblay, M. L. (2016) · Cytokine · doi:10.1016/j.cyto.2015.12.025 · Cited by 93
Mitogen-activated protein kinases as key players in osmotic stress signaling
Zhou, X., Naguro, I., Ichijo, H., & Watanabe, K. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.05.032 · Cited by 89
Breaking Free of Control: How Conventional T Cells Overcome Regulatory T Cell Suppression
Mercadante, E., & Lorenz, U. M. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00193 · Cited by 81
Bhattacharjee, S., & Nandi, S. (2017) · IUBMB Life · doi:10.1002/iub.1696 · Cited by 79
Bhattacharya, R., Ye, X.-C., Wang, R., Ling, X., McManus, M. M., Fan, F., Boulbés, D. R., & Ellis, L. M. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1605 · Cited by 74
Targeted nanoagents for the detection of cancers
McCarthy, J. R., Bhaumik, J., Karver, M. R., Erdem, S. S., & Weissleder, R. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.08.003 · Cited by 73
Voloshin, T., Alishekevitz, D., Kaneti, L., Miller, V., Isakov, E., Kaplanov, I., Voronov, E., Fremder, E., Benhar, M., Machluf, M., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0969 · Cited by 73
Gong, Z., Yang, Q., Zeng, Z., Zhang, W., Li, X., Zu, X., Deng, H., Chen, P., Liao, Q., Xiang, B., et al. (2015) · Tumor Biology · doi:10.1007/s13277-015-4156-x · Cited by 72
Schlotter, C. M., Vogt, U., Bosse, U., Mersch, B., & Waβmann, K. (2003) · Breast Cancer Research · doi:10.1186/bcr568 · Cited by 71
Cancer Vaccines in Ovarian Cancer: How Can We Improve?
Lluesma, S. M., Wolfer, A., Harari, A., & Kandalaft, L. E. (2016) · Biomedicines · doi:10.3390/biomedicines4020010 · Cited by 67
MicroRNA regulation of macrophages in human pathologies
Wei, Y., & Schober, A. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2254-6 · Cited by 67
Behind the curtain of tauopathy: a show of multiple players orchestrating tau toxicity
Huang, Y., Wu, Z., & Zhou, B. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2042-8 · Cited by 59
Hutcheson, I. R., Knowlden, J. M., Hiscox, S., Barrow, D., Gee, J. M. W., Robertson, J. F. R., Ellis, I. O., & Nicholson, R. I. (2007) · Breast Cancer Research · doi:10.1186/bcr1754 · Cited by 54
Guo, G., & Cui, Y. R. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0053-5 · Cited by 53
Risk of hepatocellular carcinoma in hepatitis B and prevention through treatment
Carey, W. D., & Sherman, M. (2009) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.76.s3.02 · Cited by 53
TGFβ Signaling in Liver Regeneration
Karkampouna, S., ten Dijke, P., Dooley, S., & Julio, M. K. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802430521 · Cited by 51
Lin, R., Zhang, C., Zheng, J., Tian, D., Lei, Z., Chen, D., Xu, Z., & Su, M. (2016) · Oncotarget · doi:10.18632/oncotarget.8356 · Cited by 51
Pleiotropic Effects of IL-2 on Cancer: Its Role in Cervical Cancer
Valle‐Mendiola, A., Gutiérrez‐Hoya, A., Lagunas-Cruz, M. D. C., Weiss‐Steider, B., & Soto‐Cruz, I. (2016) · Mediators of Inflammation · doi:10.1155/2016/2849523 · Cited by 49
Kumar, A., Sunita, P., Jha, S., & Pattanayak, S. P. (2016) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12608 · Cited by 48
Delivering cancer stem cell therapies – A role for nanomedicines?
Schätzlein, A. G. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.044 · Cited by 46
The Atypical Inhibitor of NF-κB, IκBζ, Controls Macrophage Interleukin-10 Expression
Hörber, S., Hildebrand, D. G., Lieb, W. S., Lorscheid, S., Hailfinger, S., Schulze‐Osthoff, K., & Eßmann, F. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.718825 · Cited by 46
Molecular Pathways: Targeting the PI3K Pathway in Cancer—BET Inhibitors to the Rescue
Στρατικόπουλος, Η., & Parsons, R. E. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2389 · Cited by 44
Lundstrom, K. H. (2018) · Biologics · doi:10.2147/btt.s140114 · Cited by 42
Cellular immunotherapy for malignant gliomas
Lin, Y., & Okada, H. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1214266 · Cited by 41
Chemokine regulation of neutrophil function in tumors
Bonavita, O., Massara, M., & Bonecchi, R. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2016.03.012 · Cited by 40
CREB: A Key Regulator of Normal and Neoplastic Hematopoiesis
Sandoval, S., Pigazzi, M., & Sakamoto, K. M. (2009) · Advances in Hematology · doi:10.1155/2009/634292 · Cited by 39
Promising Druggable Target in Head and Neck Squamous Cell Carcinoma: Wnt Signaling
Aminuddin, A., & Ng, P. Y. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00244 · Cited by 39
McDaniel, J. R., Pero, S. C., Voss, W. N., Shukla, G. S., Sun, Y., Schätzle, S., Lee, C., Horton, A. P., Harlow, S. P., Gollihar, J., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2123-2 · Cited by 36
Amelio, A. L., Fallahi, M., Schaub, F. X., Zhang, M., Lawani, M. B., Alperstein, A. S., Southern, M. R., Young, B. M., Wu, L., Zajac‐Kaye, M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319176111 · Cited by 35
CREB-Induced Inflammation Is Important for Malignant Mesothelioma Growth
Westbom, C. M., Shukla, A., MacPherson, M. B., Yasewicz, E. C., Miller, J. M., Beuschel, S. L., Steele, C. H., Pass, H. I., Vacek, P. M., & Shukla, A. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.06.008 · Cited by 34
Boulet, S., Daudelin, J., & Labrecque, N. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302365 · Cited by 30
Oughton, J. B., Poad, H., Twiddy, M., Collinson, M., Hiley, V., Gordon, K., Johnson, M. I., Jain, S., Noon, A. P., Chahal, R., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-017913 · Cited by 29
A novel human Smad4 mutation is involved in papillary thyroid carcinoma progression
D'inzeo, S., Nicolussi, A., Donini, C. F., Zani, M., Mancini, P., Nardi, F., & Coppa, A. (2011) · Endocrine Related Cancer · doi:10.1530/erc-11-0233 · Cited by 24
Fromm, G. J., de Silva, S., Giffin, L., Xu, X., Rose, J., & Schreiber, T. H. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0228 · Cited by 23
Genrich, G., Kruppa, M., Lenk, L., Helm, O., Broich, A., Freitag‐Wolf, S., Röcken, C., Sipos, B., Schäfer, H., & Sebens, S. (2016) · BMC Cancer · doi:10.1186/s12885-016-2191-7 · Cited by 20
Tsai, A. K., & Dávila, E. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1122158 · Cited by 20
Micropharmacology: An In Silico Approach for Assessing Drug Efficacy Within a Tumor Tissue
Karolak, A. M., & Rejniak, K. A. (2018) · Bulletin of Mathematical Biology · doi:10.1007/s11538-018-0402-x · Cited by 20
Caldeira, P. C., Sousa, A. D. A., & de Aguiar, M. C. F. (2015) · BMC Research Notes · doi:10.1186/s13104-015-1541-x · Cited by 19
Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?
Favreau, M., Vanderkerken, K., Elewaut, D. S., Venken, K., & Menu, E. (2016) · Oncotarget · doi:10.18632/oncotarget.7440 · Cited by 19
The role of nanomedicine in cell based therapeutics in cancer and inflammation.
Samarasinghe, R. M., Kanwar, R. K., & Kanwar, J. R. (2012) · PubMed Central · Cited by 18
The gep proto-oncogene Gα12 mediates LPA-stimulated activation of CREB in ovarian cancer cells
Ha, J. H., Ward, J. D., Varadarajalu, L., Kim, S. G., & Dhanasekaran, D. N. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.08.012 · Cited by 18
Saito, H., Yamada, Y., Takaya, S., Osaki, T., & Ikeguchi, M. (2015) · Surgery Today · doi:10.1007/s00595-015-1165-8 · Cited by 16
Rittase, W. B., Dong, Y., Barksdale, D., Galdzicki, Z., & Bausch, S. B. (2014) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2014.04.002 · Cited by 12
Pang, K. H., & Noon, A. P. (2017) · European Urology · doi:10.1016/j.eururo.2017.12.007 · Cited by 4
Cited by
Interleukin-1 Beta—A Friend or Foe in Malignancies?
Bent, R., Moll, L., Grabbe, S., & Bros, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082155 · Cited by 444
A Review of Cell-Based Computational Modeling in Cancer Biology
Metzcar, J., Wang, Y., Heiland, R., & Macklin, P. (2019) · JCO Clinical Cancer Informatics · doi:10.1200/cci.18.00069 · Cited by 386
The integration of inflammaging in age-related diseases
Fulop, T., Witkowski, J. M., Olivieri, F., & Larbi, A. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.09.003 · Cited by 348
Yao, D., Dong, M., Dai, C., & Wu, S. (2019) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izz149 · Cited by 338
Status and Challenges of Plant-Anticancer Compounds in Cancer Treatment
Garcia-Oliveira, P., Otero, P., Pereira, A. G., Chamorro, F., Carpena, M., Echave, J., Fraga-Corral, M., Simal-Gandara, J., & Prieto, M. A. (2021) · Pharmaceuticals · doi:10.3390/ph14020157 · Cited by 303
Metadata
- Authors
- Qu, X., Tang, Y., & Hua, S.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2018-03-20
- Volume
- 9
- Pages
- 563-563
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2791966010
- Cited by
- 301
- References
- 159
- FWCI
- 12.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.